Lilly's Triple Agonist, Retatrutide, Delivered Substantial Weight Loss and A1C Reduction, Underscoring its Potential Promise for People with Obesity and Type 2 Diabetes
Phase 3positiveRetatrutideZepboundFoundayoPositive
AI Analysis
Summary
Eli Lilly announced positive Phase 3 TRIUMPH-2 trial results for Retatrutide, demonstrating substantial weight loss and A1C reduction in patients with obesity and Type 2 Diabetes. The triple agonist showed meaningful efficacy supporting its therapeutic potential for these indications.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Substantial weight loss and A1C reduction demonstrated
Importance:8/10
Sentiment:
0.85
Phase 3 dataobesitytype 2 diabetesweight lossGLP-1 receptor agonist
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on September 29, 2026 11:09 PM